SPOTLIGHT -
Unmet Needs and Future Perspectives in Multiple Myeloma
A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.
Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma
An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.
MM: Managing Adverse Effects from Bispecific Antibodies
Experts on multiple myeloma discuss the management of adverse effects from bispecific antibodies.
Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
An expert panel discusses bispecific antibodies and their mechanisms of action in the treatment of relapsed/refractory multiple myeloma.
Treatment Options for Frontline and Relapsed Multiple Myeloma
An overview of multiple myeloma treatment options in the frontline and relapsed settings.
Patient Monitoring and Workup in Relapsed MM
Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.
Patient Profile 3: A 58-Year-Old with IgG Kappa Multiple Myeloma
Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.
Treatment Duration and Maintenance Therapy in NDMM
Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.
MAIA Trial: DRd in Patients with Newly Diagnosed MM
Insights gleaned from the MAIA trial, which researched daratumumab, lenalidomide, and dexamethasone in patients with newly diagnosed MM.
Patient Profile 2: A 74-Year-Old with Transplant-Ineligible NDMM
Myeloma experts present the case of a 74-year-old with transplant-ineligible newly diagnosed MM and offer their initial impressions.
Maintenance Therapy Regimens for Patients With Transplant-Eligible MM
An expert panel discusses maintenance therapy for patients with MM and offers insights on how induction therapy impacts treatment options.
Determining Transplant Eligibility in Newly Diagnosed MM
Experts on multiple myeloma (MM) discuss factors that determine transplant eligibility for patients who are newly diagnosed.
Triplet and Quadruplet Therapy Options for Patients With Transplant-Eligible NDMM
An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.
Patient Profile 1: A 61-Year-Old with Transplant-Eligible Newly Diagnosed MM
A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.
